EKF Diagnostics Lifts Margins and EBITDA as It Builds Platform for Five-Year Growth Plan

EKF Diagnostics Holdings ( (GB:EKF) ) has issued an update.

EKF Diagnostics reported modest top-line growth for FY 2025, with revenues up 3% to £51.6m as it continues to prioritise higher-margin product ranges and wind down non-core, low-margin lines. Point-of-care revenues in hematology and diabetes rose 6.5%, and the Life Sciences division grew 7.2%, driven by a 10% increase in β-HB sales and a new fermentation development agreement with a major diagnostics customer that is expected to contribute further in 2026 and potentially benefit from onshoring in the US. Gross margins improved to 51% from 48%, and adjusted EBITDA is expected to rise nearly 10% to £12.4m, in line with market expectations, underlining a stronger profitability base for the company’s five-year growth strategy focused on POC hematology leadership, consolidating its β-HB position and building a world-class CDMO platform. EKF also underscored its balance-sheet strength with £15.8m of year-end cash, no bank borrowings and continued strong cash generation despite deploying £5.1m on growth investment and an on-market share buy-back that has retired 5% of its shares, a move the company highlights as evidence of perceived undervaluation while carefully managing the stake of major shareholder Harwood to avoid triggering a mandatory takeover offer.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on GB:EKF Stock

According to Spark, TipRanks’ AI Analyst, GB:EKF is a Neutral.

EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.

To see Spark’s full report on GB:EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings is an AIM-listed global diagnostics company focused on point-of-care analysers in hematology and diabetes, as well as life sciences services that include specialist manufacture of enzymes and custom products for diagnostic, food and industrial applications. Headquartered in Penarth near Cardiff, the group operates five manufacturing sites across the US and Germany and sells into more than 120 countries worldwide.

Average Trading Volume: 341,496

Technical Sentiment Signal: Sell

Current Market Cap: £117.7M

For a thorough assessment of EKF stock, go to TipRanks’ Stock Analysis page.